The results of the 10-site study were announced July 14 by the National Institute of Allergic and Infectious Diseases (NIAID) and Aviron, the biopharmaceutical company in Mountain View, Calif., that licensed the vaccine technology from the U-M.
"The clinical trials demonstrate that the vaccine is safe, immunogenic, genetically stable and highly effective. It is very gratifying to see our years of effort pay off this way," said Dr. Maassab, who has been collaborating with NIAID on the vaccine since 1973. Maassab, now age 70, began his work on a live flu vaccine at U-M in 1966.
"This is a tremendous accomplishment," said Noreen M. Clark, dean of the U-M School of Public Health. "The results of the clinical trials are the successful culmination of three decades of dedication and innovation by Dr. Maassab and his research team. The vaccine is likely to have a major impact on U.S. public health in the future."
"Dr. Maassab's work is a reflection of the continuing significance of the U-M Department of Epidemiology," she added, "which has been a powerhouse in vaccinology since the 1940s, when work on influenza and polio began."
Maassab's vaccine has two advantages. First, his vaccine uses weakened and
harmless or "attenuated" live viruses that produce stronger and longer lasting
immunity than that produced with the traditional dead virus vaccine. And
second, the vaccine is administered in a n
Contact: Scott Tyrrell
University of Michigan